This newsletter presents you the following key sessions:
1. Consolidation durvalumab as a new standard of care for patients with limited-stage small-cell lung cancer without disease progression
after concurrent chemoradiotherapy
2. Nivolumab plus ipilimumab shows promise as first-line treatment for patients with unresectable hepatocellular carcinoma –
the CheckMate 9DW study
3. 177Lu-PSMA-617 leads to a better quality of life and a better pain control than a change in androgen receptor pathway inhibitor
in patients with metastatic castration-resistant prostate cancer
4. Abemaciclib improves progression-free survival in HR+/HER2- advanced breast cancer post-CDK4/6 inhibitor progression